Julie Kim will succeed Christophe Weber as CEO of Takeda in June 2026

Takeda announced that its Board of Directors made the decisions unanimously to appoint Julie Kim, currently President of Takeda’s US Business Unit, as the successor to Christope Weber, Takeda’s President, Chief Executive Officer (CEO) and Representative Director, when Mr Weber retires from the company in June 2026.

Mrs Kim will be proposed as a candidate for election to the Board at Takeda’s Annual General Shareholders Meeting held in June 2026. Mr Weber will not hold a Board seat after retiring from Takeda.

Christophe Weber commented: “For several years I have worked with the Board to ensure a smooth succession. The Board’s selection of Julie is outstanding. I have worked closely with Julie for the past six years and have witnessed first hand her values, intellect, grit and dedication to our people and patients.”

Julie Kim commented: “Takeda is a unique company, and I am deeply honored to have been chosen to lead it. Thanks to Christophe’s phenomenal leadership, Takeda has become a global biopharmaceutical powerhouse with a promising late-stage pipeline. I am excited to guide Takeda through the next phase, together with our exceptional and talented people.”

(Source: Takeda)